olanzapine
olanzapine: 8 clinical trials tracked.
olanzapine evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about olanzapine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Clinical Trial Registry Records (8)
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Primary endpoint: Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS)
A Prospective, Multicenter, Randomized Controlled Trial of Fosaprepitant Combined With Tropisetron and Multi-Day Olanzapine Versus Fosaprepitant Combined With Tropisetron and Dexamethasone for the Prevention of Delayed Nausea and Vomiting Induced by High-Dose Chemotherapy in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation
Primary endpoint: Complete Response (CR)
Olanzapine in the Prevention and Treatment of Anorexia-Cachexia Syndrome in Patients With Localized and Locally Advanced Tumors Receiving Neoadjuvant/Preoperative Chemotherapy
Primary endpoint: Proportion of patients with ≤5% weight loss
A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the Pharmacokinetics of Three SC Olanzapine Extended-release Formulations With Different Release Rates Following Single Administration in Participants With Schizophrenia or Schizoaffective Disorder
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Olanzapine (Extended-release Formulation)
A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)
Primary endpoint: Change from baseline in body mass index (BMI) Zscore at week 12
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Primary endpoint: Change in appetite
A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics
Primary endpoint: Part-2 (Disease Progression): Time to First Treatment Failure
The Effectiveness of Supplementing Supported Employment With Behavioral Skills Training
Primary endpoint: Total Weeks Worked